Investigating how tumor cells interact with platelets in metastatic breast cancer

The TGF-Beta/MUC4 Signaling Axis in Circulating Tumor Cells of Metastatic Breast Cancer

['FUNDING_FELLOWSHIP'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-10868446

This study is looking at how certain cancer cells in the blood interact with platelets and how a protein from those platelets might help cancer cells survive and become more aggressive, with the goal of finding better treatment options for people with metastatic breast cancer.

Quick facts

Phase['FUNDING_FELLOWSHIP']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF CALIFORNIA AT DAVIS (nih funded)
Locations1 site (DAVIS, UNITED STATES)
Trial IDNIH-10868446 on ClinicalTrials.gov

What this research studies

This research focuses on understanding the role of circulating tumor cells (CTCs) in metastatic breast cancer, particularly how they interact with platelets in the bloodstream. It examines the influence of a specific protein, transforming growth factor beta (TGF-β), secreted by platelets, on the behavior and survival of CTCs. The study employs various cellular and molecular techniques to analyze how TGF-β affects the expression of Mucin-4 (MUC4) in tumor cells and how this interaction may enhance the aggressiveness of cancer cells. By exploring these mechanisms, the research aims to uncover potential targets for improving treatment strategies for metastatic breast cancer.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with metastatic breast cancer who have circulating tumor cells present in their bloodstream.

Not a fit: Patients with early-stage breast cancer or those without circulating tumor cells may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that more effectively target metastatic breast cancer cells.

How similar studies have performed: Previous research has shown promising results in understanding the interactions between tumor cells and platelets, suggesting that this approach may yield valuable insights.

Where this research is happening

DAVIS, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.